NEW YORK, May 26 (GenomeWeb News) - Shares in Ciphergen this afternoon regained the roughly 7 percent they lost yesterday despite news that the company discovered biomarkers that may predict the recurrence of prostate cancer.
Already have a GenomeWeb or 360Dx account?Login Now.
An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.
The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.
Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.
In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.